KY386
Based on 1 Customer Validation
KY386 is a DHX33 helicase inhibitor with an IC50 of 0.019 μM. KY386 inhibits the cell viability of various cancer cells. KY386 induces ferroptosis in cancer cells, and induces apoptosis in some cancer cell lines. KY386 increases the intracellular levels of ROS, LPO and Fe2+, and decreases the level of GSH in cancer cells. KY386 inhibits the growth of gastric cancer and colon cancer xenografts in nude mice. KY386 is applicable to the related research on liver cancer, lung cancer, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, leukemia, renal cancer, prostate cancer, esophageal cancer, cervical cancer, brain cancer (glioblastoma) and melanoma.
For research use only. We do not sell to patients.
- Purity : 99.86%
- CAS No.: 2787598-01-8
- Formula: C21H19N5O2S
- Molecular Weight:405.47
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
|
Helicase |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U-251 | IC50 |
0.02 μM
Compound: IV-a; KY386
|
Antiproliferative activity against human U-251MG cells overexpressing DHX33 assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human U-251MG cells overexpressing DHX33 assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
|
[PMID: 37838340] |
In Vitro
KY386 (0-640 nM; 60 min) potently and selectively inhibits the helicase activity of recombinant wild-type DHX33 protein, with an IC50 of 0.019 μM[1].
KY386 (5 nM-20 μM; 48 h) potently inhibits the viability of U251-MG cancer cells overexpressing DHX33, with an IC50 of 0.02 μM[1].
KY386 (72 h) exhibits broad nanomolar anticancer activity against most of the DU145, HCT-116, HepG2, K-562, LoVo, MDA-MB-231, MIA PaCa-2, PC-3, SK-BR-3, NCI-H1299, NCI-H1975,
HCC1806, SNU-1, BT549, HCT-15, U-937, A-498, KYSE-150, A549, Daudi, Jurkat T, SNU-387, SW480, Caki-1, SNU-423, CALU-1, COLO 829, T84, U-87MG, NCI-N87, MeWo, HEEC, HGC27 and SGC7901 cells[2].
KY386 (72 h) inhibits the cell viability of human cancer cell lines A875, A375, T24, 5637, SGC7901, HGC27 and SNU668, with IC50 values ranging from 13 nM (A375) to 35 nM (A875)[2].
KY386 (0-500 nM; 24-72 h) potently induces dose- and time-dependent apoptosis in HuH-7 hepatocellular carcinoma cells and HCT116 colorectal cancer cells[2].
KY386 (0-50 nM; 4-24 h) induces dose- and time-dependent increases in intracellular ROS levels in a variety of human cancer cell lines, including HGC27, 5637, T24, A375, A875, DU145, PC3 and SNU668[2].
KY386 (0-40 nM; 8-16 h) induces a dose- and time-dependent decrease in intracellular GSH levels in HGC27 gastric cancer cells[2].
KY386 (0-60 nM; 8-16 h) induces dose- and time-dependent increases in intracellular LPO levels in HGC27, 5637, DU145 and A875 human cancer cells[2].
KY386 (0-60 nM; 16 h) induces a dose-dependent increase in intracellular Fe2+ levels in 5637, HGC27, DU145, PC3 and SNU668 human cancer cells[2].
KY386 (0-50 nM; 24 h) reduces the protein expression of lipid metabolism-related factors FADS1, FADS2 and SCD1 in human cancer cell lines HGC27, 5637, A875, PC-3 and SNU668, while exerting minimal effects on ferroptosis-related factors GPX4, SLC3A2 and SLC7A11[2].
KY386 (0-40 nM; 0-8 h) induces dose-dependent downregulation of FADS1, FADS2 and SCD1 mRNA levels in human cancer cell lines A875, A375, HGC27, T24 and DU145[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U251-MG DHX33-overexpressing glioblastoma cancer cells
-
Concentration:5 nM, 10 nM, 25 nM, 50 nM, 100 nM, 250
nM, 500 nM, 1000 nM, 2000 nM, 5000 nM, 10 μM or 20 μM -
Incubation Time:48 h
-
Result:Exhibited potent cytotoxicity against U251-MG cells, with an IC50 of 0.02 μM (20 nM).
Demonstrated moderate metabolic stability with an intrinsic clearance (CLint) of 22.4 mL/min/mg in human liver microsomes.
-
Cell Line:HuH-7, HCT116, HGC27, and DU145 human cancer cell lines
-
Concentration:20 nM, 100 nM, 500 nM (HuH-7, HCT116); 50 nM, 100 nM, 500 nM (HGC27, DU145, 24 h); 100 nM (HGC27, DU145, 48 h)
-
Incubation Time:48 h, 72 h (HuH-7, HCT116); 24 h, 48 h (HGC27, DU145)
-
Result:Induced apoptosis in a dose- and time-dependent manner in HuH-7 and HCT116 cells.
Did not effectively induce apoptosis in HGC27 and DU145 cells, even with increased dose or treatment time.
-
Cell Line:HGC27, 5637, A875, PC-3, and SNU668 human cancer cell lines
-
Concentration:20 nM, 40 nM (HGC27, SNU668); 10 nM, 20 nM, 40 nM (5637); 30 nM, 40 nM (A875); 30 nM, 50 nM (PC-3)
-
Incubation Time:24 h
-
Result:Reduced protein expression of FADS1, FADS2, and SCD1 in all tested cancer cell lines.
Had limited effect on GPX4, SLC3A2, and SLC7A11 expression.
-
Cell Line:A875, A375, HGC27, T24, and DU145 human cancer cell lines
-
Concentration:40 nM (A875, A375, HGC27, DU145); 20 nM, 40 nM (T24, DU145)
-
Incubation Time:4 h, 6 h, 8 h (A875, A375, HGC27, DU145); 6 h (T24, DU145)
-
Result:Significantly reduced mRNA levels of FADS1, FADS2, and SCD1 in a time- and dose-dependent manner in all tested cancer cell lines, with statistically significant decreases observed at all specified time points and doses.
In Vivo
KY386 (15-35 mg/kg on days 0-8, 25-45 mg/kg on days 9-20; i.p.; 2 times daily for 2 consecutive days + 3 times daily for 1 consecutive day; total duration of 21 days) significantly inhibits the growth of RASG12D-mutated colon cancer patient-derived xenografts in nude mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice (female, 5-week old)[2]
-
Dosage:25 mg/kg; 35 mg/kg; 45 mg/kg
-
Administration:i.p.; BID×2 + TID×1; 7 days
-
Result:Inhibited tumor growth in a dose-dependent manner.
Reduced mean tumor volumes compared to vehicle controls at 21 days post-treatment, with the 45 mg/kg dose showing the greatest inhibition.
Caused no significant reduction in mouse body weight, indicating minimal toxicity.
-
Animal Model:Nude mice (female, 8-week old)[2]
-
Dosage:15 mg/kg (Days 0-8) then 25 mg/kg (Days 9-20); 25 mg/kg (Days 0-8) then 35 mg/kg (Days 9-20); 35 mg/kg (Days 0-8) then 45 mg/kg (Days 9-20)
-
Administration:i.p.; BID×2 + TID×1; 21 days
-
Result:Significantly inhibited tumor growth in the RAS G12D mutant colon cancer PDX model.
Reduced mean tumor volumes compared to vehicle controls at 21 days post-treatment.
Caused no significant reduction in mouse body weight, indicating minimal toxicity.
Chemical Information
-
CAS No. 2787598-01-8
-
Appearance Solid
-
Molecular Weight 405.47
-
Formula C21H19N5O2S
-
Color White to off-white
-
SMILES
COC1=CC=C2N=C(NC2=C1)NC(C3=C(N(C(C)=C3)C4=C(C=C(S4)C)C#N)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (246.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang Y, et al. Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents. Bioorg Med Chem Lett. 2023;96:129505. [Content Brief]
[2]. Tang X, et al. An RNA Helicase DHX33 Inhibitor Shows Broad Anticancer Activity via Inducing Ferroptosis in Cancer Cells. ACS Omega. 2024;9(26):28372-28384. Published 2024 Jun 17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4663 mL | 12.3314 mL | 24.6627 mL | 61.6568 mL |
| 5 mM | 0.4933 mL | 2.4663 mL | 4.9325 mL | 12.3314 mL | |
| 10 mM | 0.2466 mL | 1.2331 mL | 2.4663 mL | 6.1657 mL | |
| 15 mM | 0.1644 mL | 0.8221 mL | 1.6442 mL | 4.1105 mL | |
| 20 mM | 0.1233 mL | 0.6166 mL | 1.2331 mL | 3.0828 mL | |
| 25 mM | 0.0987 mL | 0.4933 mL | 0.9865 mL | 2.4663 mL | |
| 30 mM | 0.0822 mL | 0.4110 mL | 0.8221 mL | 2.0552 mL | |
| 40 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | |
| 50 mM | 0.0493 mL | 0.2466 mL | 0.4933 mL | 1.2331 mL | |
| 60 mM | 0.0411 mL | 0.2055 mL | 0.4110 mL | 1.0276 mL | |
| 80 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL | |
| 100 mM | 0.0247 mL | 0.1233 mL | 0.2466 mL | 0.6166 mL |
Keywords
- KY386
- 2787598-01-8
- KY 386
- KY-386
- DNA/RNA Synthesis
- Ferroptosis
- Apoptosis
- Reactive Oxygen Species (ROS)
- DHX33 helicase inhibitor
- ferroptosis
- apoptosis
- U251-MG cells
- A875 cells
- A375 cells
- T24 cells
- 5637 cells
- SGC7901 cells
- HGC27 cells
- SNU668 cells
- liver cancer
- lung cancer
- pancreatic cancer
- colorectal cancer
- gastric cancer
- breast cancer
- leukemia
- renal cancer
- prostate cancer
- esophageal cancer
- cervical cancer
- brain cancer (glioblastoma)
- melanoma
- Nude mice
- Inhibitor
- inhibitor
- inhibit